- Home
- SBFG vs TLSI Comparison
SBFG vs TLSI Comparison
Compare SBFG & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFG
- TLSI
- Stock Information
- Founded
- SBFG 1983
- TLSI 2010
- Country
- SBFG United States
- TLSI United States
- Employees
- SBFG N/A
- TLSI N/A
- Industry
- SBFG Major Banks
- TLSI Medical Specialities
- Sector
- SBFG Finance
- TLSI Health Care
- Exchange
- SBFG Nasdaq
- TLSI Nasdaq
- Market Cap
- SBFG 132.3M
- TLSI 150.0M
- IPO Year
- SBFG N/A
- TLSI N/A
- Fundamental
- Price
- SBFG $20.38
- TLSI $4.60
- Analyst Decision
- SBFG
- TLSI Strong Buy
- Analyst Count
- SBFG 0
- TLSI 5
- Target Price
- SBFG N/A
- TLSI $10.90
- AVG Volume (30 Days)
- SBFG 24.4K
- TLSI 102.3K
- Earning Date
- SBFG 10-23-2025
- TLSI 11-13-2025
- Dividend Yield
- SBFG 2.87%
- TLSI N/A
- EPS Growth
- SBFG 2.59
- TLSI N/A
- EPS
- SBFG 1.83
- TLSI N/A
- Revenue
- SBFG $61,225,000.00
- TLSI $35,990,000.00
- Revenue This Year
- SBFG N/A
- TLSI $56.79
- Revenue Next Year
- SBFG N/A
- TLSI $54.15
- P/E Ratio
- SBFG $11.42
- TLSI N/A
- Revenue Growth
- SBFG 9.45
- TLSI 45.50
- 52 Week Low
- SBFG $16.56
- TLSI $3.42
- 52 Week High
- SBFG $24.48
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- SBFG 40.83
- TLSI 45.93
- Support Level
- SBFG $20.00
- TLSI $4.41
- Resistance Level
- SBFG $21.74
- TLSI $5.10
- Average True Range (ATR)
- SBFG 0.65
- TLSI 0.30
- MACD
- SBFG -0.16
- TLSI -0.07
- Stochastic Oscillator
- SBFG 16.10
- TLSI 20.59
About SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.